PT  - JOURNAL ARTICLE
AU  - Poppelaars, Felix
AU  - Eskandari, Siawosh K.
AU  - Damman, Jeffrey
AU  - Seelen, Marc A.
AU  - Faria, Bernardo
AU  - da Costa, Mariana Gaya
TI  - A non-muscle myosin heavy chain 9 genetic variant is associated with graft failure following kidney transplantation
AID  - 10.1101/2022.03.29.22272996
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.29.22272996
4099  - http://medrxiv.org/content/early/2022/04/04/2022.03.29.22272996.short
4100  - http://medrxiv.org/content/early/2022/04/04/2022.03.29.22272996.full
AB  - Background Despite current matching efforts to identify optimal donor-recipient pairs in kidney transplantation, alloimmunity remains a major proponent of late transplant failure. While kidney allocation based on human leukocyte antigen (HLA) matching has markedly prolonged short-term graft survival, new data suggests that additional genetic parameters in donor-recipient matching could help improve the long-term outcomes. Here, we studied the impact of a recently discovered non-muscle myosin heavy chain 9 gene (MYH9) polymorphism on kidney allograft failure.Methods We conducted a prospective observational cohort study, analyzing the DNA of 1,271 kidney donor-recipient transplant pairs from a single academic hospital for the MYH9 rs11089788 C>A polymorphism. The association of the MYH9 genotype with the risk of graft failure (primary outcome), biopsy-proven acute rejection (BPAR), and delayed graft function (DGF) (secondary outcomes) were determined.Results The MYH9 polymorphism in the donor was not associated with 15-year death-censored kidney graft survival, whereas a trend was seen for the association between the MYH9 polymorphism in the recipient and graft failure (recessive model, P=0.056). Having the AA-genotype of the MYH9 polymorphism in recipients was associated with a higher risk of DGF (P=0.031) and BPAR (P=0.021), although the significance was lost after adjustment for potential confounders (P=0.15 and P=0.10, respectively). The combined presence of the MYH9 polymorphism in donor-recipient pairs was significantly associated with long-term kidney allograft survival (P=0.036), in which recipients with an AA-genotype receiving a graft with an AA-genotype had the worst outcome. After adjustment for covariates, this combined genotype remained significantly associated with 15-year death-censored kidney graft survival (HR 1.68, 95%-CI: 1.05 – 2.70, P=0.031).Conclusions Our results reveal that recipients with an AA-genotype MYH9 polymorphism receiving a donor kidney with an AA-genotype, have a significantly elevated risk of graft failure after kidney transplantation.Key pointsIn recipients, the MYH9 SNP was associated with delayed graft function and biopsy-proven acute rejection after kidney transplantation, although the significance was lost in multivariable analysis.Presence of the MYH9 variant in both the donor and recipient significantly associated with long-term kidney allograft survival in multivariable analysis.Our present findings suggests that matching donor-recipient transplant pairs based on the MYH9 polymorphism may attenuate the risk of graft loss.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study and the study protocol was given by the Institutional Review Board of the University Medical Center Groningen in Groningen, The Netherlands (Medical Ethical Committee 2014/077). The study protocol adhered to the Declaration of Helsinki. All subjects provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.APOL1Apolipoprotein L1 geneBPARBiopsy-proven acute rejectionCITCold ischemia timeCKDChronic kidney diseaseDBDDonation after circulatory deathDCDDonation after brain deathDGFDelayed graft functionESKDEnd-stage kidney diseaseHLAHuman leukocyte antigenHRHazard ratioMYH9Myosin heavy chain 9 genePRAPanel-reactive antibodyOROdds ratioSNPSingle-nucleotide polymorphismWITWarm ischemia time